Fig. 7 | Signal Transduction and Targeted Therapy

Fig. 7

From: Lipocalin-2 drives brain metastatic progression through reciprocal tumor-microenvironment interactions in lung cancer

Fig. 7

Preventive inhibition of IL-1β–IL-1R signaling reversed LCN2 expression to inhibit BM. a Schematic outlining prevention and treatment protocols in the BM mouse model. b Safety profile of the Anakinra- and vehicle-treated groups; the data are presented as the means ± SDs, n = 4; two-sided t-test, ns not significant. c, d Tumor inhibition rate and survival analysis in the prevention cohort, normalized to vehicle-treated BM-bearing mice (n = 5). e Bioluminescence imaging (BLI) on days 0, 5, and 10 posttreatment in BM-bearing mice. The treatment groups included vehicle, anakinra (100 mg/kg daily), SH4-54 (10 mg/kg every 3 days), and anakinra + SH4-54. The data are presented as the means ± SDs, n = 9; two-way ANOVA, ns not significant, * P < 0.05, ***P < 0.001. f Summary diagram of the proposed mechanism (created with BioRender.com). LCN2 lipocalin-2, BM brain metastases, IHC immunohistochemistry

Back to article page